Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 18:15:349-360.
doi: 10.2147/CEOR.S405079. eCollection 2023.

In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data

Chisato Izumi  1 , Rei Matsuyama  2 , Kaoru Yamabe  2 , Kosuke Iwasaki  3 , Tomomi Takeshima  3 , Shannon M E Murphy  4 , Lida Teng  5 , Ataru Igarashi  5   6
Affiliations

In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data

Chisato Izumi et al. Clinicoecon Outcomes Res. .

Abstract

Purpose: Heart failure (HF) is a serious public health burden that is rapidly increasing in the aging population. Valvular heart disease (VHD) is a known etiology of heart failure (HF); however, the impact of VHD on outcomes of patients with HF has not been well-studied in Japan. This study aimed to determine the rates of VHD in Japanese patients admitted for HF and explore associations of VHD with in-hospital outcomes through a claim-based analysis.

Patients and methods: We analyzed claims data from 86,763 HF hospitalizations (January 2017 through December 2019) from the Medical Data Vision database. Common etiologies of HF were examined, then hospitalizations were categorized into those with VHD and those without. Covariate-adjusted models were used to explore the association of VHD with in-hospital mortality, length of stay, and medical cost.

Results: Of 86,763 hospitalizations for HF, 13,183 had VHD and 73,580 did not. VHD was the second most frequent etiology of HF (15.2%). The most frequent type of VHD was mitral regurgitation (36.4% of all hospitalizations with VHD), followed by aortic stenosis (33.7%) and aortic regurgitation (16.4%). There was no significant difference in in-hospital mortality between hospitalizations with VHD vs those without (9.0% vs 8.9%; odds ratio [95% CI]: 1.01 [0.95-1.08]; p=0.723). Hospitalizations with VHD were associated with significantly longer length of stay (26.1 vs 24.8 days; incident rate ratio [95% CI]: 1.05 [1.03-1.07]; p<0.001) and higher medical costs (1536 vs 1195 thousand yen; rate ratio [95% CI]: 1.29 [1.25-1.32]; p<0.001).

Conclusion: VHD was a frequent etiology of HF that was associated with significant medical resource use. Future studies are needed to investigate whether timely VHD treatment could reduce HF progression and its associated healthcare resource utilization.

Keywords: etiology; hospital claims; length of stay; medical costs; medical data vision; mortality.

PubMed Disclaimer

Conflict of interest statement

CI received consult fees from Abbott Japan LLC and Edwards Lifesciences Limited. RM and KY are employees of Edwards Lifesciences Limited. SM is an employee of Edwards Lifesciences Corporation and has Edwards stock. KI and TT are employee of Milliman Inc., which has received consult fees from Edwards Lifesciences Limited. AI received research fund from Edwards Lifesciences Limited and Boston Scientific Inc.; consult fees and lecture fees from Abbott Inc., GSK Japan Inc., Medtronic Inc., MSD Inc., Moderna Japan Inc., Pfizer Japan Inc., Sanofi-Pasteur Inc., Novartis Pharma K.K., AbbVie GK, Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Asahi Kasei Pharma Inc., Novo Nordisk Pharma Inc., Eisai Inc., Beckton Dickinson and Company, Maruho Co. Ltd., Ono Pharmaceutical Inc., Sato Pharmaceutical Inc., Sumitomo Dainippon Pharma Inc., and Eli Lilly Japan K.K., outside the submitted work; research grants from Taiho Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Beckton & Dickinson Inc., CSL Behring Japan Inc., Gilead Science K.K., Takeda Pharmaceutical Inc., Boston Scientific Japan Inc., DeSC Healthcare Inc., Otsuka Pharmaceutical K.K., Varian Medical systems and Intuitive Surgical GK., outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

None
Graphical abstract
Figure 1
Figure 1
Attrition diagram. For patients admitted for heart failure multiple times, all hospitalizations during the study period were analyzed. Due to overlap between the exclusion groups, the sum of the exclusions was not equal to the total number of hospitalizations excluded.
Figure 2
Figure 2
Common etiologies of heart failure. (A). Percentage of patients admitted for heart failure with common heart failure etiologies. Patients with multiple etiologies of heart failure were counted under each type. (B). Composition of patients admitted for heart failure with VHD alone and combined with ischemic heart disease or cardiomyopathy.
Figure 3
Figure 3
Types of VHD in patients admitted for heart failure. Patients with more than one type of VHD were counted under each type.
Figure 4
Figure 4
Adjusted in-hospital outcomes during heart failure hospitalization in patients stratified by the presence or absence of VHD. (A). Adjusted in-hospital mortality. (B) Adjusted length of stay. (C) Adjusted medical cost. Bars indicate 95% confidence interval.
See this image and copyright information in PMC

References

    1. Savarese G, Lund LH. Global public health burden of heart failure. Heart Fail Rev. 2017;3(1):7–11. doi:10.15420/cfr.2016:25:2 - DOI - PMC - PubMed
    1. Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 2014;1(1):4–25. doi:10.1002/ehf2.12005 - DOI - PubMed
    1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–1146. doi:10.1136/hrt.2003.025270 - DOI - PMC - PubMed
    1. Li H, Hastings MH, Rhee J, Trager LE, Roh JD, Rosenzweig A. Targeting age-related pathways in heart failure. Circ Res. 2020;126(4):533–551. doi:10.1161/CIRCRESAHA.119.315889 - DOI - PMC - PubMed
    1. Lazzarini V, Mentz RJ, Fiuzat M, Metra M, O’Connor CM. Heart failure in elderly patients: distinctive features and unresolved issues. Eur J Heart Fail. 2013;15(7):717–723. doi:10.1093/eurjhf/hft028 - DOI - PMC - PubMed